Vicarious Surgical Inc. (RBOT) Income Statement
RBOT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRBOT revenue and net income
RBOT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RBOT quarterly EPS vs estimates
Vicarious Surgical beat the analyst EPS estimate in 4 of the last 8 quarters.
RBOT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.4M | $2.1M | $1.9M | $1.9M | $316,000 | — | — |
| Gross profit | −$1.4M | −$2.1M | −$1.9M | −$1.9M | −$316,000 | — | — |
| Research & development | $33.6M | $40.2M | $47.6M | $43.9M | $22.1M | $9.8M | $7.5M |
| Sales, general & admin | $15.2M | $21.9M | $26.9M | $36.2M | $16.2M | $3.2M | $2.3M |
| Total operating expenses | $49.5M | $64.4M | $78.8M | $80.1M | $38.2M | $13.0M | $9.8M |
| Operating income | −$51.0M | −$66.6M | −$80.7M | −$80.1M | −$38.2M | −$13.0M | −$9.8M |
| Interest income | $973,000 | $3.3M | $4.3M | $1.4M | $20,000 | $113,000 | — |
| Interest expense | — | $0 | $25,000 | $200,000 | $89,000 | $3,000 | $0 |
| Income before taxes | −$50.2M | −$63.2M | −$71.1M | $5.2M | −$35.2M | −$12.9M | −$9.3M |
| Income taxes | — | — | −$1 | −$84.0M | −$227,000 | $3,000 | −$67,860 |
| Net income | −$50.2M | −$63.2M | −$71.1M | $5.2M | −$35.2M | −$12.9M | −$9.3M |
| EBITDA | −$48.8M | −$61.1M | −$69.2M | $6.5M | −$34.8M | −$12.8M | −$9.7M |
| EPS (diluted) | −$8.37 | −$10.86 | −$13.56 | −$19.50 | −$3.98 | $0.00 | — |
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $2.1M | $0 | $0 | $0 | $3.5M | $0 | $0 |
| Cost of revenue | $183,000 | $291,000 | $352,000 | $413,000 | $369,000 | $542,000 | $507,000 | $524,000 | $521,000 | $525,000 | $447,000 | $641,000 |
| Gross profit | −$183,000 | −$291,000 | −$352,000 | −$413,000 | −$369,000 | −$542,000 | −$507,000 | −$524,000 | −$521,000 | −$525,000 | −$447,000 | −$641,000 |
| Research & development | $5.0M | $7.5M | $7.6M | $9.1M | $9.4M | $7.9M | $10.8M | $10.9M | $10.0M | $7.9M | $13.0M | $12.7M |
| Sales, general & admin | $2.1M | $2.6M | $3.5M | $4.5M | $6.3M | $6.5M | $7.0M | $6.8M | $6.1M | $7.1M | $8.3M | $8.7M |
| Total operating expenses | $7.3M | $9.9M | $11.2M | $13.5M | $15.7M | $14.4M | $17.8M | $17.7M | $16.1M | $15.0M | $21.4M | $21.5M |
| Operating income | −$7.5M | −$10.2M | −$11.5M | −$13.5M | −$15.7M | −$15.0M | −$17.8M | −$17.7M | −$16.1M | −$15.5M | −$21.4M | −$21.5M |
| Interest income | $40,000 | $105,000 | $158,000 | $264,000 | $446,000 | $594,000 | $802,000 | $918,000 | $975,000 | $966,000 | $946,000 | $1.0M |
| Interest expense | — | — | — | — | — | $0 | $0 | $0 | $0 | $22,000 | $1,000 | $1,000 |
| Income before taxes | −$7.3M | −$10.5M | −$11.1M | −$13.2M | −$15.4M | −$13.9M | −$17.1M | −$15.2M | −$17.0M | −$13.1M | −$15.7M | −$15.3M |
| Income taxes | — | — | — | — | — | −$477,724 | — | −$1 | $477,724 | −$4.1M | −$447,000 | −$1.0M |
| Net income | −$7.3M | −$10.5M | −$11.1M | −$13.2M | −$15.4M | −$13.9M | −$17.1M | −$15.2M | −$17.0M | −$13.1M | −$15.7M | −$15.3M |
| EBITDA | −$7.1M | −$10.2M | −$10.7M | −$12.8M | −$15.0M | −$13.4M | −$16.6M | −$14.7M | −$16.5M | −$12.6M | −$15.3M | −$14.9M |
| EPS (diluted) | — | −$1.65 | −$1.91 | −$2.23 | −$2.58 | −$2.43 | −$2.87 | −$2.86 | −$2.70 | −$0.06 | −$3.60 | −$4.80 |
| Gross margin | — | — | — | — | — | −25.9% | — | — | — | −15.2% | — | — |
| Operating margin | — | — | — | — | — | −716.7% | — | — | — | −450.5% | — | — |
| Net margin | — | — | — | — | — | −666.3% | — | — | — | −380.0% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RBOT's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RBOT financial results
Vicarious Surgical reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $50.2 million. Diluted earnings per share came to −$8.37.
See the RBOT stock overview for the latest quote and news, or the RBOT chart for price history and technical indicators.
RBOT income statement FAQ
Does Vicarious Surgical have revenue?
Vicarious Surgical reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Vicarious Surgical profitable?
No. Vicarious Surgical reported a net loss of $50.2 million in fiscal 2025.
How much does Vicarious Surgical spend on research and development?
Vicarious Surgical spent $33.6 million on research and development in fiscal 2025.
What are Vicarious Surgical's earnings per share?
Vicarious Surgical earned $-8.37 per diluted share in fiscal 2025, compared with $-10.86 a year earlier.
When does Vicarious Surgical's fiscal year end?
Vicarious Surgical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.